Hydropothecary Announces Bought Deal Offering to be Extended to Quebec

Hydropothecary Announces Bought Deal Offering to be Extended to Quebec

Hydropothecary Announces Bought Deal Offering to be Extended to Quebec

GATINEAU, QC--(Marketwired - November 02, 2017) - The Hydropothecary Corporation THCX

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Hydropothecary Corporation ("THCX" or the "Company") THCX announced today that its previously announced bought deal offering of 60,000 convertible debenture units of the Company for aggregate gross proceeds of $60,000,000 will be extended to include the Province of Québec. Accordingly, the units will be offered and sold by way of a bought deal public offering in all provinces and territories of Canada and the Company will file a short form prospectus qualifying the issuance of the units in all provinces and territories of Canada pursuant to National Instrument 44-101 - Short Form Prospectus Distributions.

The offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

About The Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides sungrown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary's branding, cannabis product offering, patient service standards and product pricing are consistent with Hydropothecary's positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For Investor Relations Inquiries:

Jennifer Smith

Manager of Financial Reporting and Investor Relations

1-866-438-THCX (8429)

invest@THCX.com

www.THCX.com



For Media Inquiries:

Julie Beun

Publicist and Media Relations

julie@thehydropothecary.com

613-371-9060

or

Adam Miron

Director

819-639-5498

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!